Monday, 19 December 2011

Cancer Drug Imitinef Mercilet - NOW IN INDIA







The human body is at all times prone to dissimilar types of diseases. But, there are a number of diseases, which cause entire dejection into the patients, because these incurable diseases do not have any cure. Blood cancer, scientifically well-known as leukaemia is one such disease, which in anticipation of now did not have any kind of treatment that can provide entire relief without any type of adverse side effects. However, researchers each and every one over the world put in their most excellent efforts and discovered Imitinef Mercilet, the miracle drug for curing blood cancer. Furthermore, Imitinef Mercilet acts only through the cancerous cells and does not harm some other vital organ in your body.

Imitinef Mercilet works in a miraculous way as it creates a blockade in the improvement of the irregular enzyme that causes leukaemia. This obstruction developed by Imitinef Mercilet not only restricts the abnormal growth of the blood cells but also switches off the production of the protein that aids in the enlargement of the cancerous cells. It is a well-known fact all the way through the world that cancer treatment is a costly concern, which most of the people are not capable to bear. Keeping this in mind, Adyar Cancer Institute in Chennai has taken the inventiveness step of providing free treatment forleukaemia patients.

Administration of Imitinef Mercilet verbally at Adyar Cancer Institute has provided optimistic results to people suffering on or after blood cancer. Eminent cancer specialists working in Adyar Cancer Institute have exposed that the body rapidly absorbsImitinef Mercilet particularly when the patient take the drug orally as nearly ninety-eight percent of the drug, straight away goes into the bloodstream and starts its remedial effect. Though liver is the organ, where the metabolism of the drug takes position but to hand is no adverse effect on this vital organ. 

Imitinef Mercilet medicine available at free of cost in following hospitals:

1. Kovai-Sri Ramakrishna hospital.

2. Adyar cancer institute in Chennai, Bangalore, Trivandrum.

Consequently, patients because of all over the world can avail this free treatment and live a healthy as well as carefree life.

Detailed AnalysisAccording to this message, India's Adyar Cancer Institute is distributing, free of charge, a medicine named 'Imitinef Mercilet' that cures blood cancer. The message is circulating rapidly via email and is also making its way around the Internet via blogs, forums and social networking websites.

The Adyar Cancer Institute is a real health facility located in the city of Chennai, India and, as its name implies, it indeed specializes in cancer treatment and research. The Adyar Cancer Institute has achieved great results in the treatment and research of cancer since its establishment in 1954.

A spokesperson at the Adyar Cancer Institute to ask about the veracity of the message.


Only the Part of this message is true. The medicine Imitinef is available free for only qualified persons and not for all. It is free for those who have admitted in the hospital for treatment.
'Imitinef Mercilet' is apparently an alternative spelling of the drug Imatinib mesylate which is used in the treatment of some forms of leukemia along with other types of cancer. Imatinib, often referred to a "Gleevec", has proved to be an effective treatment for some forms of cancers. However, "blood cancer" is a generalized term for cancers that affect the blood, lymphatic system or bone marrow. The three types of blood cancer are listed as leukemia, lymphoma, and multiple myeloma. These three malignancies require quite different kinds of treatments. While drugs (including Imatinib), along with other treatments such as radiation can help to slow or even stop the progress of these cancers, there is currently no single drug treatment that can be said to actually cure all such cancers.


Moreover, it should be noted that Imitinef is available for cancer patients in many different health facilities around the world, not just the Adyar Cancer Institute.
******************************************************************

Source: http://www.currentweek.net/2010/08/cancer-drug-imitinef-mercilet-now-in.html

Posted by Society For Better Treatment at 05:23 2 comments

Imitinef Mercilet for Leukemia Patients





'Imitinef Mercilet' is a medicine which cures blood cancer. Its available free of cost at "Adyar Cancer Institute in Chennai". 
Create Awareness. It might help someone. 

Forward to as many as u can.

Cancer Institute in Adyar, Chennai 

Address: 
East Canal Bank Road , Gandhi Nagar 
Adyar 
Chennai -600020 
Landmark: Near Michael School
Imitinef Mercilet medicine available at free of cost in following hospitals:


1. Kovai-Sri Ramakrishna hospital.


2. Adyar cancer institute in Chennai, Bangalore, Trivandrum.

Detailed AnalysisAccording to this message, India's Adyar Cancer Institute is distributing, free of charge, a medicine named 'Imitinef Mercilet' that cures blood cancer. The message is circulating rapidly via email and is also making its way around the Internet via blogs, forums and social networking websites.

The Adyar Cancer Institute is a real health facility located in the city of Chennai, India and, as its name implies, it indeed specializes in cancer treatment and research. The Adyar Cancer Institute has achieved great results in the treatment and research of cancer since its establishment in 1954.

A spokesperson at the Adyar Cancer Institute to ask about the veracity of the message.


Only the Part of this message is true. The medicine Imitinef is available free for only qualified persons and not for all. It is free for those who have admitted in the hospital for treatment.
'Imitinef Mercilet' is apparently an alternative spelling of the drug Imatinib mesylate which is used in the treatment of some forms of leukemia along with other types of cancer. Imatinib, often referred to a "Gleevec", has proved to be an effective treatment for some forms of cancers. However, "blood cancer" is a generalized term for cancers that affect the blood, lymphatic system or bone marrow. The three types of blood cancer are listed as leukemia, lymphoma, and multiple myeloma. These three malignancies require quite different kinds of treatments. While drugs (including Imatinib), along with other treatments such as radiation can help to slow or even stop the progress of these cancers, there is currently no single drug treatment that can be said to actually cure all such cancers.


Moreover, it should be noted that Imitinef is available for cancer patients in many different health facilities around the world, not just the Adyar Cancer Institute.
******************************************************************


Leukemia or blood cancer occurs mostly in the bone marrow, blood, or the lymph nodes due to the development of malignancies in these vital areas of the body. A patient suffering from any one of the malignancies requires immediate leukemia treatment as malignancy in the blood will easily affect the lymph nodes and the bone marrow and in the same manner malignancy in the bone marrow will spread in the blood and the lymph nodes as all the three are related to the immune system of the body. There are several types of treatment available for blood cancer out of which the drug Imitinef Mercilet has proved the most effective treatment for chronic lymphocytic leukemia.
Many of you might have heard of the drug called imatinib mesylate used for some types of leukemia treatment and for treatment of other types of cancer. Imitinef Mercilet is the altered spelling of the same drug, which some of the cancer institutes in India supply free of cost to patients who suffer from that particular type of blood cancer and take admission in those hospitals where the doctors use the drug to treat the patients without charging any money for the treatment. However, it is essential that if any of your near and dear one is suffering from blood cancer, you should first consult a specialist to find out whether the patient is suffering from the type of cancer that is curable with the help of this drug.
Imitinef Mercilet or Imatinib mesylate has proved as an effective leukemia treatment because this drug has direct effect on the protein that helps in the growth of the cancer cells. Moreover, this drug does not have any kind of long-term adverse side effect so it does not harm the other vital organs of the body, which in turn enhances the chances of recovery in the patient treated with this drug. Of course, there are some nominal side effects, which occur during the period of the treatment and wane off as soon as the patient recovers and stops the use of the drug. However, before starting the use of this drug it is always advisable to consult a specialist and take his advice so that the patient suffering from this painful disease can get complete relief.

Related Posts

    No related posts found

You may also like -



Posted by Society For Better Treatment at 05:17 2 comments

Blood Cancer Cure with Imitinef Mercilet





'Imitinef Mercilet' is a medicine which cures blood cancer. Its available free of cost at "Adyar Cancer Institute in Chennai". 
Create Awareness. It might help someone. 

Forward to as many as u can.

Cancer Institute in Adyar, Chennai 

Address: 
East Canal Bank Road , Gandhi Nagar 
Adyar 
Chennai -600020 
Landmark: Near Michael School
Imitinef Mercilet medicine available at free of cost in following hospitals:

1. Kovai-Sri Ramakrishna hospital.

2. Adyar cancer institute in Chennai, Bangalore, Trivandrum.

Imitinef Mercilet medicine available at free of cost in following hospitals:

1. Kovai-Sri Ramakrishna hospital.

2. Adyar cancer institute in Chennai, Bangalore, Trivandrum.

Detailed AnalysisAccording to this message, India's Adyar Cancer Institute is distributing, free of charge, a medicine named 'Imitinef Mercilet' that cures blood cancer. The message is circulating rapidly via email and is also making its way around the Internet via blogs, forums and social networking websites.

The Adyar Cancer Institute is a real health facility located in the city of Chennai, India and, as its name implies, it indeed specializes in cancer treatment and research. The Adyar Cancer Institute has achieved great results in the treatment and research of cancer since its establishment in 1954.

A spokesperson at the Adyar Cancer Institute to ask about the veracity of the message.

Only the Part of this message is true. The medicine Imitinef is available free for only qualified persons and not for all. It is free for those who have admitted in the hospital for treatment.
'Imitinef Mercilet' is apparently an alternative spelling of the drug Imatinib mesylate which is used in the treatment of some forms of leukemia along with other types of cancer. Imatinib, often referred to a "Gleevec", has proved to be an effective treatment for some forms of cancers. However, "blood cancer" is a generalized term for cancers that affect the blood, lymphatic system or bone marrow. The three types of blood cancer are listed as leukemia, lymphoma, and multiple myeloma. These three malignancies require quite different kinds of treatments. While drugs (including Imatinib), along with other treatments such as radiation can help to slow or even stop the progress of these cancers, there is currently no single drug treatment that can be said to actually cure all such cancers.

Moreover, it should be noted that Imitinef is available for cancer patients in many different health facilities around the world, not just the Adyar Cancer Institute.
********************************************

The human body is always prone to different types of diseases. However, there are some diseases, which cause total dejection in the patients, as these fatal diseases do not have any cure. Blood cancer, scientifically known as leukaemia is one such disease, which until now did not have any type of treatment that could provide complete relief without any type of adverse side effects. Nevertheless, researchers all over the world put in their best efforts and discovered Imitinef Mercilet, the miracle drug for curing blood cancer. Moreover, Imitinef Mercilet acts only with the cancerous cells and does not harm any other vital organ in your body.
Imitinef Mercilet works in a miraculous way as it creates a blockade in the development of the abnormal enzyme that causes leukaemia. This blockage developed by Imitinef Mercilet not only restricts the abnormal growth of the blood cells but also switches off the production of the protein that aids in the growth of the cancerous cells. It is a well-known fact throughout the world that cancer treatment is a costly affair, which most of the people are unable to bear. Keeping this in mind, Adyar Cancer Institute in Chennai has taken the initiative step of providing free treatment for leukaemia patients.
Administration of Imitinef Mercilet orally at Adyar Cancer Institute has provided positive results to people suffering from blood cancer. Eminent cancer specialists working in Adyar Cancer Institute have discovered that the body quickly absorbs Imitinef Mercilet especially when the patient takes the drug orally as nearly ninety-eight percent of the drug, immediately goes into the bloodstream and starts its curative effect. Although liver is the organ, where the metabolism of the drug takes place but there is no adverse effect on this vital organ. Therefore, patients from all over the world can avail this free treatment and live a healthy and carefree life.

Related Posts

    No related posts found

You may also like -



Source: 

Posted by Society For Better Treatment at 05:14 5 comments

Tuesday, 6 December 2011

Society For Better Treatment also raised demonstration against the Kidnapping of Dr. Bidyut Nath, a barbaric incident

Posted by Society For Better Treatment at 02:57 0 comments

Monday, 5 December 2011

Spatiotemporal Signals Guide Stem Cell Changes Enabling Engineering Of Cartilage Replacements

A lab discovery is a step toward implantable replacement cartilage, holding promise for knees, shoulders, ears and noses damaged by osteoarthritis, sports injuries and accidents.

Self-assembling sheets of mesenchymal stem cells permeated with tiny beads filled with growth factor formed thicker, stiffer cartilage than previous tissue engineering methods, researchers at Case Western Reserve University have found. A description of the research is published in the Journal of Controlled Release.

"We think that the capacity to drive cartilage formation using the patient's own stem cells and the potential to use this approach without lengthy culture time prior to implantation makes this technology attractive," said Eben Alsberg, associate professor in the departments of Biomedical Engineering and Orthopaedic Surgery, and senior author of the paper.

Alsberg teamed with biomedical engineering graduate students Loran D. Solorio and Phuong N. Dang, undergraduate student Chirag D. Dhami, and Eran L. Vieregge, a student at Case Western Reserve School of Medicine.

The team put transforming growth factor beta-1 in biodegradable gelatin microspheres distributed throughout the sheet of stem cells rather than soak the sheet in growth factor.

The process showed a host of advantages, Alsberg said.

The microspheres provide structure, similar to scaffolds, creating space between cells that is maintained after the beads degrade. The spacing results in better water retention - a key to resiliency.

The gelatin beads degrade at a controllable rate due to exposure to chemicals released by the cells. As the beads degrade, growth factor is released to cells at the interior and exterior of the sheet, providing more uniform cell differentiation into neocartilage.

The rate of microsphere degradation and, therefore, cell differentiation, can be tailored by the degree to which the microsphere are cross-linked. Within the microspheres, the polymer is connected by a varying number of threads. The more of these connections, or cross-links, the longer it takes for enzymes the cell secretes to enter and break down the material.

The researchers made five kinds of sheets. Those filled with: sparsely cross-linked microspheres containing growth factor, highly cross-linked microspheres containing growth factor, sparsely cross-linked microspheres with no growth factor, highly cross-linked microspheres with no growth factor, and a control with no microspheres. The last three were grown in baths containing growth factor.

After three weeks in a petri dish, all sheets containing microspheres were thicker and more resilient than the control sheet. The sheet with sparsely crosslinked microspheres grew into the thickest and most resilient neocartilage.

The results indicate that the sparsely cross-linked microspheres, which degraded more rapidly by cell-secreted enzymes, provided a continuous supply of growth factor throughout the sheets that enhanced the uniformity, extent, and rate of stem cell differentiation into cartilage cells, or chondrocytes.

The tissue appeared grossly similar to articular cartilage, the tough cartilage found in the knee: rounded cells surrounded by large amounts of a matrix containing glycosaminoglycans. Called GAG for short, the carbohydrate locks water ions in the tissue, which makes the tissue pressure-resistant.

Testing also showed that this sheet had the highest amount of type II collagen - the main protein component of articular cartilage.

Although the sheet was significantly stiffer than control sheets, the mechanics still fell short of native cartilage. Alsberg's team is now working on a variety of ways to optimize the process and make replacement cartilage tough enough for the wear and tear of daily life.

One major advantage of this system is that it may avoid the troubles and expense of growing the cartilage fully in the lab over a long period of time, and instead permit implantation of a cartilage sheet into a patient more rapidly.

Because the sheets containing microspheres are strong enough to be handled early during culturing, the researchers believe sheets just a week or two old could be used clinically. The mechanical environment within the body could further enhance cartilage formation and increase strength and resiliency of the tissue, completing maturation.



Source:

Case Western Reserve University. "Spatiotemporal Signals Guide Stem Cell Changes Enabling Engineering Of Cartilage Replacements." Medical News Today. MediLexicon, Intl., 5 Dec. 2011. Web.
5 Dec. 2011. <http://www.medicalnewstoday.com/releases/238648.php>

Case Western Reserve University. (2011, December 5). "Spatiotemporal Signals Guide Stem Cell Changes Enabling Engineering Of Cartilage Replacements." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/238648.php.
Posted by Society For Better Treatment at 04:37 0 comments

Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments

 
As cancer researchers continue to identify genetic mutations driving different cancer subtypes, they are also creating a catalog of possible targets for new treatments. The University of Michigan Comprehensive Cancer Center and Michigan Center for Translational Pathology (MCTP) recently completed a pilot study aimed at solving the practical challenges involved in quickly and systematically sequencing genetic material from patients with advanced or treatment-resistant cancer in order to match them with existing clinical trials based on the biomarkers identified.
"We're talking about more than just examining a few genes where mutations are known to occur, or even about a hundred genes," says co-lead investigator Dan Robinson, Ph.D., a post-doctoral fellow at MCTP. "We're talking about the ability to sequence more than 20,000 genes and look not just for individual genetic mutations, but at combinations of mutations."
The exploratory study, known as the Michigan Oncology Sequencing Project (MI-ONCOSEQ), found that identifying a patient's "mutational landscape" provides a promising approach for identifying which trials may best help a patient, the researchers say. Their findings were recently published in Science Translational Medicine.
"High-throughput sequencing harnesses the latest technological advances to process millions of pieces of genetic information, allowing us to map a cancer's genetic aberrations," says co-lead investigator Sameek Roychowdhury, M.D., Ph.D., a clinical lecturer in hematology and oncology at the U-M Medical School. "Using this technique to identify biomarker-driven treatment options really opens the door for personalized oncology, but it also presents a number of logistical challenges, chief among them making the results available cost-effectively and in a clinically relevant timeframe."
"A decade or two ago, this type of sequencing would have cost many millions or even billions of dollars, but the technology is advancing so rapidly, we're now talking in terms of thousands -- which makes widespread use a real possibility," he adds.
Cancer can arise from a variety of genetic alterations including rearrangements, additions, deletions and substitutions within the genetic code.
"Different sequencing processes are required to find different types of alterations," Roychowdhury says. "But to be cost-effective, there must be a balancing act between a broad analysis and a deep analysis."
The study began by testing the researchers' sequencing strategy on prostate cancer tumors that had been grown in mice. Later, two patients were enrolled in a clinical pilot: one with colorectal cancer and one with melanoma. Potential clinical trials were identified for both patients.
However, the researchers caution, not all patients will match an existing study. Some patients with a given mutation may be excluded because they have, for example, prostate cancer, but a trial is only enrolling breast cancer patients. The researchers believe that this approach also provides an opportunity to approach clinical trials in a new way, moving from a tissue-specific focus toward genetic aberrations shared across cancer types.
Still, enrolling in a trial does not guarantee a patient will benefit from the treatment, the researchers caution.
Hurdles to widespread implementation include the need for a multidisciplinary Sequencing Tumor Board to interpret the complex sequencing results, management of the necessary computational resources, and a process for dealing with incidental genetic findings revealed by the sequencing -- such as a risk for hemochromatosis, a genetic disorder that causes the body to absorb too much iron.
Achieving a four-week turnaround time for results is important because that's how long patients are usually required to wait for unsuccessful treatments to leave their systems before starting a clinical trial.
"Once some of the practical and technological hurdles are cleared, we envision an array of mutation and pathway-based trials for available targeted therapies, with eligibility based on molecular assessment," says senior investigator Arul Chinnaiyan, M.D., Ph.D., director of MCTP, Howard Hughes Medical Institute Investigator, and S.P. Hicks Professor of Pathology at the U-M Medical School. "Moreover, if patients are treated with matching targeted therapies and develop secondary resistance, it could also help reveal the mechanisms of resistance and inform future trials for combination therapies."
Chinnaiyan says the work was made possible only by collaboration and teamwork. U-M physicians Moshe Talpaz, M.D., Stephen Gruber, M.D., Ph.D., and Kenneth Pienta, M.D. played key roles in the clinical implementation of this exploratory protocol, he notes.
Researchers hope this type of sequencing will become more widely available over the next 5 to 10 years. Cancer patients are encouraged to speak to their doctors about clinical trial opportunities.

Published: Wednesday, November 30, 2011 - 22:33 in Health & Medicine

Source: University of Michigan Health System

Posted by Society For Better Treatment at 04:28 0 comments
Subscribe to: Posts (Atom)